Please login to the form below
giant cell tumour of the bone
This page shows the latest giant cell tumour of the bone news and features for those working in and with pharma, biotech and healthcare.
FDA clears Amgen's Xgeva for rare bone condition
US approval provides alternative to surgery for use in giant cell tumour of the bone. ... The US FDA yesterday gave a green to the use of Amgen's Xgeva (denosumab) to treat adults and some adolescents with giant cell tumour of the bone (GCTB).
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
